Innoviva, Inc.
As of Oct 22, 2026, Innoviva is in Stage 4, the downtrend phase, now in week 9 (since Aug 24, 2026). It closed at $21.06, 13.1% below its 52-week high and below its 200-day average, which is rising.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is INVA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
INVA among Biotechnology130th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …130 | INVA | Stage 4 · wk 9 | 71 | +4.1% |
Innoviva: quick answers
What stage is Innoviva in?
As of Oct 22, 2026, Innoviva (INVA) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 24, 2026 and is in week 9. What the four stages mean
Is Innoviva in an uptrend?
No. Innoviva is in a Stage 4 downtrend. It trades 3.6% below its 200-day average, which is rising.
How far is Innoviva from its 52-week high?
Innoviva closed at $21.06 on Oct 22, 2026, 13.1% below its 52-week high of $24.24. Its 52-week low is $17.57.
How has Innoviva performed over the past year?
As of Oct 22, 2026, Innoviva is up 21.0% over the past year and up 6.0% so far in 2026.
Which sector and industry is Innoviva in?
Innoviva is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.